Search results for "Opioid response"

showing 6 items of 6 documents

Does pain intensity predict a poor opioid response in cancer patients?

2011

Abstract Aim The aim of this study was to test the hypothesis that initial pain intensity is not a predictive factor of poor opioid response in advanced cancer patients, as suggested by a recent work. Methods A secondary analysis of one-hundred-sixty-seven patients referred for treatment of cancer-related pain was conducted. Pain intensity at admission was recorded and patients were divided in three categories of pain intensity: mild, moderate and severe. Patients were offered a treatment with opioid dose titration, according to department policy. Data regarding opioid doses and pain intensity were collected after dose titration was completed. Four levels of opioid response were considered:…

MaleCancer ResearchOpioid responseopioid response in cancer patientPainOpioidSettore MED/42 - Igiene Generale E ApplicataSecondary analysisNeoplasmsmedicineHumansProspective StudiesCancer painKarnofsky Performance StatusAdverse effectAgedPain Measurementpain intensityAnalgesicsAnalysis of VarianceAssessment tools; Cancer pain; Opioid response; Aged; Analgesics Opioid; Analysis of Variance; Female; Humans; Karnofsky Performance Status; Male; Middle Aged; Neoplasms; Pain; Pain Measurement; Prospective Studies; Treatment Outcome; Cancer Research; Oncologybusiness.industryCancerMiddle Agedmedicine.diseaseAdvanced cancerIntensity (physics)Predictive factorAnalgesics OpioidAssessment toolsTreatment OutcomeOncologyOpioidAnesthesiapain intensity; opioid response in cancer patients; trial clinicoFemaletrial clinicoCancer painbusinessmedicine.drugEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Pain intensity as prognostic factor in cancer pain management

2015

Aim The aim of this study was to prospectively assess the prognostic value of initial pain intensity and its duration in advanced cancer patients. Methods A prospective study was conducted in a sample of patients with cancer requiring pain control. Patients underwent standard analgesic strategies used in our palliative care units. Pain intensity was measured at admission (T0) and after successful dose titration or opioid/route switching within a week (Ts). Patients were also asked about their pain intensity reported 15 days before admission (T-15). Doses of opioids and duration of opioid use were recorded. Patients were also assessed for the presence of incident pain, neuropathic pain, alco…

MalePalliative careSettore MED/42 - Igiene Generale E ApplicataSeverity of Illness IndexPain assessmentNeoplasms80 and overProspective StudiesCancer painProspective cohort studyCancerPain MeasurementAged 80 and overPrognostic factorAnalgesicsPalliative CareAssessment tools; Cancer; Cancer pain; Opioid; Opioid analgesics; Opioid response; Pain assessment; Pain intensity; Pain measurement; Prognostic factors; Aged; Aged 80 and over; Analgesics; Analgesics Opioid; Female; Humans; Logistic Models; Male; Middle Aged; Neoplasms; Neuralgia; Pain; Pain Management; Pain Measurement; Palliative Care; Prognosis; Prospective Studies; Stress Psychological; Treatment Outcome; Severity of Illness Index; Anesthesiology and Pain MedicineAssessment toolMiddle AgedPrognosisAnalgesics OpioidAssessment toolsTreatment OutcomeAnesthesiaNeuropathic painFemalemedicine.drugOpioid responsePain assessmentAnalgesicPainOpioidPain intensityPrognostic factorsStressOpioid analgesicAssessment tools; Cancer; Cancer pain; Opioid; Opioid analgesics; Opioid response; Pain assessment; Pain intensity; Pain measurement; Prognostic factors; Anesthesiology and Pain MedicinemedicineHumansPain ManagementAdverse effectAgedbusiness.industryAnesthesiology and Pain MedicineLogistic ModelsOpioidOpioid analgesicsPsychologicalNeuralgiaCancer painbusinessStress Psychological
researchProduct

The effects of low doses of pregabalin on morphine analgesia in advanced cancer patients

2012

Abstract OBJECTIVES: The aim of this study was to evaluate the opioid response in patients receiving morphine and pregabalin, independently from the presumed pain mechanisms, in comparison with patients receiving morphine treatment only. METHODS: A multicenter prospective randomized controlled study was carried out in a sample of 70 advanced cancer patients with pain requiring strong opioids. Thirty-five patients (group MO) were randomized to receive sustained-release morphine using initial doses of 60 mg/day. Thirty-five patients (group MO-PR) were randomized to start the same morphine doses and pregabalin in increasing doses, starting with 25 mg/day up to 150 mg/day in one week. The follo…

Malecancer painAnalgesicPregabalinPregabalinPainSettore MED/42 - Igiene Generale E Applicatalaw.inventionDose-Response Relationshipadvanced cancer patientDrug TherapyQuality of lifeRandomized controlled triallawassessment toolsNeoplasmsmedicineHumansDrug Interactionslow doses pregabalinBrief Pain Inventorygamma-Aminobutyric AcidPain Measurementneuropathic painAnalgesicsDose-Response Relationship DrugMorphinebusiness.industryassessment tools; cancer pain; neuropathic pain; opioid response; Analgesics; Dose-Response Relationship Drug; Drug Interactions; Drug Therapy Combination; Female; Humans; Italy; Male; Morphine; Neoplasms; Pain; Pain Measurement; Palliative Care; Pregabalin; Treatment Outcome; gamma-Aminobutyric Acid; Anesthesiology and Pain Medicine; Neurology (clinical)Palliative CareAdvanced cancerTreatment OutcomeAnesthesiology and Pain MedicineItalyOpioidlow doses pregabalin; advanced cancer patients; epidemiologic studyopioid responseAnesthesiaCombinationepidemiologic studyMorphineDrug Therapy CombinationFemaleNeurology (clinical)Drugbusinessmedicine.drug
researchProduct

Tools for identifying cancer pain of predominantly neuropathic origin and opioid responsiveness in cancer patients.

2009

Neuropathic pain (NP) is a difficult issue, particularly in cancer which is a dynamic condition where multiple pain etiologies are concomitantly present. Cancer pain is often labeled as mixed mechanism pain and is not easily classified as exclusively nociceptive or NP. The aim of this study was to explore the value of evaluation tools such as Neuropathic Pain Questionnaire (NPQ), complete and short form (NPQ-SF), Leeds Assessment of Neuropathic Signs and Symptoms (LANSS) and Neuropathic Pain Symptom Inventory (NPSI). The secondary outcome was to evaluate the response to opioid titration, according to the hierarchical classification of definite, possible and unlikely NP. A consecutive sample…

Malemedicine.medical_specialtyPainOpioidSensitivity and SpecificityRoute of administrationassessment toolsInternal medicineNeoplasmsmedicineassessment tools; Cancer pain; neuropathic pain; opioid response; Aged; Analgesics Opioid; Female; Humans; Male; Neoplasms; Pain; Pain Measurement; Sensitivity and Specificity; Treatment Outcome; Anesthesiology and Pain Medicine; Neurology; Neurology (clinical)HumansCancer painAgedPain Measurementtools for cancer painneuropathic painopioid responsivenessAnalgesicsbusiness.industryCancerPain scaleneuropathic cancer painmedicine.diseaseAnalgesics OpioidAnesthesiology and Pain MedicineNociceptionTreatment OutcomeNeurologyOpioidopioid responseAnesthesiaNeuropathic painEtiologyFemaleNeurology (clinical)businessCancer painmedicine.drugThe journal of pain
researchProduct

Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: A randomized, controlled, double-blind, crossover, double-dose study

2000

Pain not responsive to morphine is often problematic. Animal and clinical studies have suggested that N-methyl-d-aspartate (NMDA) antagonists, such as ketamine, may be effective in improving opioid analgesia in difficult pain syndromes, such as neuropathic pain. A slow bolus of subhypnotic doses of ketamine (0.25 mg/kg or 0.50 mg/kg) was given to 10 cancer patients whose pain was unrelieved by morphine in a randomized, double-blind, crossover, double-dose study. Pain intensity on a 0 to 10 numerical scale; nausea and vomiting, drowsiness, confusion, and dry mouth, using a scale from 0 to 3 (not at all, slight, a lot, awful); Mini-Mental State Examination (MMSE) (0- 30); and arterial pressur…

Anesthesiology and Pain MedicineOpioid responseKetamineNeurology (clinical)Cancer painAdverse effectNeuropathic painNMDA- antagonistNursing (all)2901 Nursing (miscellaneous)Randomized controlled epidemiologic study
researchProduct

Addition of a second opioid may improve opioid response in cancer pain: preliminary data

2004

Recent experimental data suggest a possible use of an opioid combination to improve analgesia. In cancer patients, a rapid opioid escalation due to either worsening of the pain condition or the development of tolerance is a critical phase, as this condition is associated with a negative prognosis. The aim of this study was to assess the effects of adding a second opioid at low doses in patients with a poor analgesic benefit after dose escalation. Fourteen patients receiving strong opioids who had increased their dosage more than 100% in the last week unsuccessfully were randomly chosen to add a second opioid to the first using an initial equivalent dosage of 20% of the previous therapy. The…

AdultMalecancer painMaximum Tolerated DosePain medicineAnalgesicPainRisk AssessmentSeverity of Illness IndexDrug Administration ScheduleStatistics Nonparametriclaw.inventionPharmacotherapyRandomized controlled triallawNeoplasmsMedicineHumansTerminally IllProspective StudiesKarnofsky Performance StatusAdverse effectAgedPain MeasurementProbabilityTerminal CareDose-Response Relationship DrugMorphinebusiness.industryMiddle AgedClinical trialAnalgesics OpioidFentanylTreatment OutcomeOncologyOpioidopioid responseAnesthesiaopioid treatmentDrug Therapy CombinationFemaleCancer painbusinessmedicine.drug
researchProduct